<DOC>
	<DOCNO>NCT00293202</DOCNO>
	<brief_summary>Etanercept novel anti-inflammatory agent currently use patient rheumatoid arthritis . We examine whether etanercept effective improve nutritional status hemodialysis patient consequence ability decrease inflammation . Hemodialysis patient end stage renal disease high mortality rate . In individual patient , mortality associate low serum albumin concentration , marker poor nutritional status , elevate C-reactive protein , marker inflammation . Since effort improve nutrition dietary intake successful , inflammation think play key role determine nutritional status . Recently , show malnutrition , inflammation , atherosclerosis closely related patient chronic renal failure . It hypothesis suppression cycle inflammation , malnutrition , vascular injury cause atherosclerosis improve survival dialysis patient . This study design examine whether suppression inflammatory response accomplish safely etanercept determine suppression improve nutritional status clinical outcome hemodialysis patient poor nutritional status evidence inflammation .</brief_summary>
	<brief_title>Safety Efficacy Study Effect Etanercept Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Presence end stage renal disease History Tuberculosis History Recurrent Infection Recent AMI , Cancer within previous 5 year Presence Hepatitis B , Hepatitis C , HIV , systemic lupus erythematosis , presence transcutaneous access ( external catheter )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>etanercept</keyword>
	<keyword>malnutrition</keyword>
	<keyword>inflammation</keyword>
	<keyword>hemodialysis</keyword>
</DOC>